株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙SALE
市場調査レポート

IVD (体外診断) 市場:製品、技術、用途、エンドユーザー別 - 世界の機会分析および業界予測

IVD Market by Product Type (Reagents, Instruments and Software & Services), by Technique, by Application, by End Users - Global Opportunity Analysis and Industry Forecast, 2017-2023

発行 Allied Market Research 商品コード 563263
出版日 ページ情報 英文 240 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.58円で換算しております。
Back to Top
IVD (体外診断) 市場:製品、技術、用途、エンドユーザー別 - 世界の機会分析および業界予測 IVD Market by Product Type (Reagents, Instruments and Software & Services), by Technique, by Application, by End Users - Global Opportunity Analysis and Industry Forecast, 2017-2023
出版日: 2017年09月01日 ページ情報: 英文 240 Pages
概要

当レポートでは、世界のIVD (体外診断) 市場について調査し、市場の動向と製品別、技術別、用途別、エンドユーザー別、地域別動向、および市場に参入する主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場の定義と範囲
  • 主な調査結果
  • ポーターズファイブフォース分析
  • 市場シェア分析
  • 市場動向
    • 促進因子
    • 阻害因子
    • 機会

第4章 製品装置別市場

  • 概要
  • 試薬
  • 装置
  • ソフトウェア・サービス

第5章 技術別市場

  • 概要
  • 免疫診断
  • 血液検査
  • 分子診断
  • 組織診断
  • 臨床化学
  • その他

第6章 用途別市場

  • 感染症
  • 心臓病
  • 免疫系不全
  • 神経疾患
  • 胃腸疾患
  • その他

第7章 エンドユーザー別市場

  • 独立型試験所
  • 病院
  • 学術・医学学校
  • ポイントオブケア検査
  • その他

第8章 地域別市場

  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ

第9章 企業プロファイル

目次
Product Code: LI 17336

In vitro diagnostics (IVD) is the technique in which medical devices and reagents are used to examine specimens such as blood, urine, stool, tissues, and other body fluids, which are derived from the human body to detect diseases, conditions, and infections. These tests can be performed in stand-alone laboratories, and hospitals- Some of the significant technologies incorporated in vitro diagnostics include polymerase chain reaction (PCR), microarray techniques, sequencing technology, and mass spectrometry, which are used for test sample preparation. Incessant innovations in IVD product design and technology have encouraged doctors and researchers to shift their focus from traditional diagnostic methods to personalized medicines.

There is a growth in need of IVD testing due to increase in incidences of chronic and infectious diseases and rise in geriatric population prone to immunological disorders. Moreover, increased application of personalized medicines and widespread knowledge of rare diseases boost the growth of the IVD market. In addition, increase in incidences of colorectal cancer, neurological disorders, and gynecological diseases boost the adoption of IVD devices and reagents. On the contrary, stringent government regulations and unfavorable reimbursement policies limit the growth of the market. The global IVD market is accounted for $61,103 million in 2016, and is estimated to reach at $84,647 million by 2023, growing at a CAGR of 4.6% from 2017-2023.

The market is segmented on the basis of product type, techniques, application, end-user, and geography. By product type, the market is categorized into reagents, instruments, and software & services. On the basis of techniques, it is categorized into immunodiagnostics, blood testing, molecular diagnostics, tissue diagnostics, clinical chemistry, and other IVD techniques. By application, the market is classified into infectious diseases, cancer, cardiac diseases, immune system disorders, nephrological diseases, gastrointestinal diseases, and other indications. Based on end-user, it is divided into hospitals, academic and medical schools, point of care testing, and others. By geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

  • The study provides an in-depth analysis of the global IVD market, with current trends and future estimations to elucidate the investment pockets.
  • Comprehensive analysis of factors that drive and restrict the growth of the market is provided.
  • The report provides a quantitative analysis to help the stakeholders to capitalize on prevailing market opportunities.
  • Extensive analysis of different segments facilitates to understand various products of the market.
  • Key players are profiled and their strategies are analyzed thoroughly, which predict the competitive outlook of the market.

KEY MARKET SEGMENTS

By Product Type

  • Reagents
  • Instruments
  • Software and Services

By Techniques

  • Immunodiagnostics
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Chemiluminescence Immunoassays (CLIAS)
  • Fluorescence Immunoassays (FIAS)
  • Colorimetric Immunoassays (CIS)
  • Rapid Tests
  • Enzyme-Linked Immunospot Assays (ELISPOT)
  • Radioimmunoassay
  • Western Blot
  • Blood Testing
  • Molecular Diagnostics
  • Polymerase Chain Reaction (PCR)
  • Isothermal Nucleic Acid Amplification Technology (INAAT)
  • Hybridization
  • DNA Diagnostics
  • Microarrays
  • Others
  • Tissue Diagnostics
  • Clinical Chemistry
  • Basic Metabolic Panel
  • Liver Panel
  • Lipid Profile
  • Thyroid Function Panel
  • Renal Profile
  • Electrolyte Panel
  • Specialty Chemicals
  • Other IVD Techniques

By Application

  • Infectious Diseases
  • Cancer
  • Cardiac Diseases
  • Immune System Disorders
  • Nephrological Diseases
  • Gastrointestinal Diseases
  • Other Indications

By End Users

  • Standalone Laboratory
  • Hospitals
  • Academic and Medical Schools
  • Point of Care Testing
  • Others

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Latin America
  • Middle East
  • Africa
  • List of players profiled in the report
  • Thermo Fisher Scientific Inc.
  • Alere Inc.
  • Biomerieux
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • Becton Dickinson and Company
  • Bio-Rad Laboratories
  • Bayer AG
  • Sysmex Corporation
  • Johnson & Johnson

Table of Contents

CHAPTER 1 INTRODUCTION

  • 1.1 REPORT DESCRIPTION
  • 1.2 KEY BENEFITS
  • 1.3 KEY MARKET SEGMENTS
  • 1.4 RESEARCH METHODOLOGY
    • 1.4.1 Secondary research
    • 1.4.2 Primary research
    • 1.4.3 Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

  • 2.1 CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

  • 3.1 MARKET DEFINITION AND SCOPE
  • 3.2 KEY FINDINGS
    • 3.2.1 Top investment pockets
    • 3.2.2 Top winning strategies
  • 3.3 PORTERS FIVE FORCES ANALYSIS
    • 3.3.1 Bargaining power of suppliers
    • 3.3.2 Bargaining power of buyers
    • 3.3.3 Threat of new entrants
    • 3.3.4 Threat of substitute
    • 3.3.5 Competitive rivalry
  • 3.4 MARKET SHARE ANALYSIS, 2016
  • 3.5 MARKET DYNAMICS
    • 3.5.1 Drivers
      • 3.5.1.1 Increasing incidence of chronic and infectious diseases
      • 3.5.1.2 Technological advancements in IVD
      • 3.5.1.3 Emergence of minimal invasive technologies
      • 3.5.1.4 Increasing government expenditures on healthcare
      • 3.5.1.5 Increase in popularity of personalized medicine approach
    • 3.5.2 Restraint
      • 3.5.2.1 Unclear reimbursement policies
      • 3.5.2.2 Stringent regulatory policies
    • 3.5.3 Opportunity
      • 3.5.3.1 Potential opportunities for outsourcing
      • 3.5.3.2 Convergence of new technologies

CHAPTER 4 IVD MARKET, BY PRODUCT TYPE

  • 4.1 OVERVIEW
    • 4.1.1 Market size and forecast
  • 4.2 REAGENTS
    • 4.2.1 Key market trends
    • 4.2.2 Key growth factors and opportunities
    • 4.2.3 Market size and forecast
  • 4.3 INSTRUMENTS
    • 4.3.1 Key market trends
    • 4.3.2 Key growth factors and opportunities
    • 4.3.3 Market size and forecast
  • 4.4 SOFTWARE AND SERVICES
    • 4.4.1 Key market trends
    • 4.4.2 Key growth factors and opportunities
    • 4.4.3 Market size and forecast

CHAPTER 5 IVD MARKET, BY TECHNIQUE

  • 5.1 OVERVIEW
    • 5.1.1 Market size and forecast
  • 5.2 IMMUNODIAGNOSTICS
    • 5.2.1 Key market trends
    • 5.2.2 Key growth factors and opportunities
    • 5.2.3 Market size and forecast
    • 5.2.4 Enzyme-linked immunosorbent assay (ELISA)
      • 5.2.4.1 Market size and forecast
      • 5.2.4.2 Chemiluminescence immunoassay (CLIA)
      • 5.2.4.2.1 Market size and forecast
      • 5.2.4.3 Fluorescence immunoassay (FIA)
      • 5.2.4.3.1 Market size and forecast
      • 5.2.4.4 Colorimetric immunoassay (CI)
      • 5.2.4.4.1 Market size and forecast
    • 5.2.5 Rapid tests
      • 5.2.5.1 Market size and forecast
    • 5.2.6 Enzyme-linked immunospot (ELISPOT)
      • 5.2.6.1 Market size and forecast
    • 5.2.7 Radioimmunoassay (RIA)
      • 5.2.7.1 Market size and forecast
    • 5.2.8 Western blot
      • 5.2.8.1 Market size and forecast
  • 5.3 BLOOD TESTING
    • 5.3.1 Key market trends
    • 5.3.2 Key growth factors and opportunities
    • 5.3.3 Market size and forecast
  • 5.4 MOLECULAR DIAGNOSTICS
    • 5.4.1 Key market trends
    • 5.4.2 Key growth factors and opportunities
    • 5.4.3 Market size and forecast
    • 5.4.4 Polymerize chain reaction (PCR)
      • 5.4.4.1 Market size and forecast
    • 5.4.5 Isothermal nucleic acid technology (INAAT)
      • 5.4.5.1 Market size and forecast
    • 5.4.6 Hybridization
      • 5.4.6.1 Market size and forecast
    • 5.4.7 DNA diagnostics
      • 5.4.7.1 Market size and forecast
    • 5.4.8 Microarray
      • 5.4.8.1 Market size and forecast
    • 5.4.9 Others
      • 5.4.9.1 Market size and forecast
  • 5.5 TISSUE DIAGNOSTICS
    • 5.5.1 Key market trends
    • 5.5.2 Key growth factors and opportunities
    • 5.5.3 Market size and forecast
  • 5.6 CLINICAL CHEMISTRY
    • 5.6.1 Key market trends
    • 5.6.2 Key growth factors and opportunities
    • 5.6.3 Market size and forecast
    • 5.6.4 Basic metabolic panel
      • 5.6.4.1 Market size and forecast
    • 5.6.5 Liver panel
      • 5.6.5.1 Market size and forecast
    • 5.6.6 Renal profile
      • 5.6.6.1 Market size and forecast
    • 5.6.7 Lipid profile
      • 5.6.7.1 Market size and forecast
    • 5.6.8 Thyroid function panel
      • 5.6.8.1 Market size and forecast
    • 5.6.9 Electrolyte panel
      • 5.6.9.1 Market size and forecast
    • 5.6.10 Speciality chemicals
      • 5.6.10.1 Market size and forecast
  • 5.7 OTHER IVD TECHNIQUES
    • 5.7.1 Key market trends
    • 5.7.2 Key growth factors and opportunities
    • 5.7.3 Market size and forecast

CHAPTER 6 IVD MARKET, BY APPLICATION

  • 6.1 INFECTIOUS DISEASES
    • 6.1.1 Key market trends
    • 6.1.2 Key growth factors and opportunities
    • 6.1.3 Market size and forecast
  • 6.2 CANCER
    • 6.2.1 Key market trends
    • 6.2.2 Key growth factors and opportunities
    • 6.2.3 Market size and forecast
  • 6.3 CARDIAC DISEASES
    • 6.3.1 Key market trends
    • 6.3.2 Key growth factors and opportunities
    • 6.3.3 Market size and forecast
  • 6.4 IMMUNE SYSTEM DISORDERS
    • 6.4.1 Key market trends
    • 6.4.2 Key growth factors and opportunities
    • 6.4.3 Market size and forecast
  • 6.5 NEPHROLOGICAL DISEASES
    • 6.5.1 Key market trends
    • 6.5.2 Key growth factors and opportunities
    • 6.5.3 Market size and forecast
  • 6.6 GASTROINTESTINAL DISEASES
    • 6.6.1 Key market trends
    • 6.6.2 Key growth factors and opportunities
    • 6.6.3 Market size and forecast
  • 6.7 OTHERS INDICATIONS
    • 6.7.1 Key market trends
    • 6.7.2 Key growth factors and opportunities
    • 6.7.3 Market size and forecast

CHAPTER 7 IVD MARKET BY END USERS

  • 7.1 STANDALONE LABORATORIES
    • 7.1.1 Market size and forecast
  • 7.2 HOSPITALS
    • 7.2.1 Key market trends
    • 7.2.2 Key growth factors and opportunities
    • 7.2.3 Market size and forecast
  • 7.3 ACADEMIC AND MEDICAL SCHOOLS
    • 7.3.1 Key market trends
    • 7.3.2 Key growth factors and opportunities
    • 7.3.3 Market size and forecast
  • 7.4 POINT OF CARE TESTING
    • 7.4.1 Key market trends
    • 7.4.2 Key growth factors and opportunities
    • 7.4.3 Market size and forecast
  • 7.5 OTHERS END-USER
    • 7.5.1 Key market trends
    • 7.5.2 Key growth factors and opportunities
    • 7.5.3 Market size and forecast

CHAPTER 8 IVD MARKET BY GEOGRAPHY

  • 8.1 OVERVIEW
    • 8.1.1 Market size and forecast
  • 8.2 NORTH AMERICA
    • 8.2.1 Key market trends
    • 8.2.2 Key growth factors and opportunities
    • 8.2.3 Market size and forecast
    • 8.2.4 U.S.
      • 8.2.4.1 Market size and forecast
    • 8.2.5 Canada
      • 8.2.5.1 Market size and forecast
    • 8.2.6 Mexico
      • 8.2.6.1 Market size and forecast
  • 8.3 EUROPE
    • 8.3.1 Key market trends
    • 8.3.2 Key growth factors and opportunities
    • 8.3.3 Market size and forecast
    • 8.3.4 Germany
      • 8.3.4.1 Market size and forecast
    • 8.3.5 France
      • 8.3.5.1 Market size and forecast
    • 8.3.6 UK
      • 8.3.6.1 Market size and forecast
    • 8.3.7 SPAIN
      • 8.3.7.1 Market size and forecast
    • 8.3.8 ITALY
      • 8.3.8.1 Market size and forecast
    • 8.3.9 Rest of Europe
      • 8.3.9.1 Market size and forecast
  • 8.4 ASIA-PACIFIC
    • 8.4.1 Key market trends
    • 8.4.2 Key growth factors and opportunities
    • 8.4.3 Market size and forecast
    • 8.4.4 India
      • 8.4.4.1 Market size and forecast
    • 8.4.5 China
      • 8.4.5.1 Market size and forecast
    • 8.4.6 Japan
      • 8.4.6.1 Market size and forecast
    • 8.4.7 Australia
      • 8.4.7.1 Market size and forecast
    • 8.4.8 South Korea
      • 8.4.8.1 Market size and forecast
    • 8.4.9 Rest of Asia-Pacific
      • 8.4.9.1 Market size and forecast
  • 8.5 LAMEA
    • 8.5.1 Key market trends
    • 8.5.2 Key growth factors and opportunities
    • 8.5.3 Market size and forecast
    • 8.5.4 Latin America
      • 8.5.4.1 Market size and forecast
    • 8.5.5 Middle East
      • 8.5.5.1 Market size and forecast
    • 8.5.6 Africa
      • 8.5.6.1 Market size and forecast

CHAPTER 9 COMPANY PROFILES

  • 9.1 THERMO FISHER SCIENTIFIC INC.
    • 9.1.1 Company overview
    • 9.1.2 Business performance
    • 9.1.3 Key strategies and development
  • 9.2 ALERE INC.
    • 9.2.1 Company overview
    • 9.2.2 Business performance
    • 9.2.3 Key strategies and developments
  • 9.3 BIOMERIEUX
    • 9.3.1 Company overview
    • 9.3.2 Business performance
    • 9.3.3 Key strategies and developments
  • 9.4 DANAHER CORPORATION
    • 9.4.1 Company overview
    • 9.4.2 Business performance
    • 9.4.3 Key strategies and development
  • 9.5 F. HOFFMANN-LA ROCHE AG
    • 9.5.1 Company overview
    • 9.5.2 Business performance
    • 9.5.3 Key strategies and developments
  • 9.6 BECTON DICKINSON AND COMPANY
    • 9.6.1 Company overview
    • 9.6.2 Business performance
    • 9.6.3 Key strategies and development
  • 9.7 BIO-RAD LABORATORIES
    • 9.7.1 Company overview
    • 9.7.2 Business performance
    • 9.7.3 Key strategies and developments
  • 9.8 BAYER AG
    • 9.8.1 Company overview
    • 9.8.2 Business performance
    • 9.8.3 Key strategies and development
  • 9.9 SYSMEX CORPORATION
    • 9.9.1 Company overview
    • 9.9.2 Business performance
    • 9.9.3 Key strategies and developments
  • 9.10 JOHNSON & JOHNSON
    • 9.10.1 Company overview
    • 9.10.2 Business performance
    • 9.10.3 Key strategies and development
Back to Top